Research Overview
CJC-1295 / Ipamorelin Blend is a co-lyophilised research preparation combining two distinct growth-hormone secretagogues that have been studied in parallel across endocrine literature. CJC-1295 without DAC is a tetra-substituted GHRH analogue, also referenced as Modified GRF(1-29) or CJC-1295 No-DAC, engineered with four amino-acid substitutions that improve enzymatic stability.
Ipamorelin is a pentapeptide classified in literature as a selective ghrelin-receptor agonist. The two compounds engage separate receptor populations on the somatotroph and have been co-administered in protocols examining pulsatile GH release.
The vial in this listing contains 10mg combined lyophilised peptide powder, sealed under inert conditions for laboratory reconstitution. Each batch is supplied with a Certificate of Analysis documenting HPLC purity and mass-spectrometry confirmation. The product is supplied strictly for in-vitro and pre-clinical research applications and is not intended for human or veterinary administration.
Mechanism Studied in Research
The blend has been studied in models examining two complementary axes of growth-hormone control. CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs, with downstream activation of adenylate cyclase, elevation of intracellular cAMP, and PKA-mediated phosphorylation of CREB.
Ipamorelin acts primarily through ghrelin-receptor signaling and is investigated for its selective stimulation of growth-hormone release with limited off-target endocrine activity. When combined in research models, the two peptides are evaluated for coordinated effects on pulsatile GH secretion and downstream IGF-1 signaling.
Researchers use this blend in controlled laboratory settings to explore GH-axis modulation, receptor pathway activity, somatotroph response, and comparative behavior against related secretagogue systems.
Research Applications
Pulsatile GH secretion modelling. The blend has been used in research to examine whether simultaneous GHRH-receptor activation and ghrelin-receptor signaling produce coordinated growth-hormone pulse activity.
GH-axis investigation. Researchers use CJC-1295 / Ipamorelin in laboratory models to study somatotroph response, receptor activation, GH release patterns, and downstream IGF-1 signaling.
Body-composition and metabolic-tissue research. Pre-clinical investigations have measured effects of repeated GH-secretagogue exposure on adipose tissue markers, lean-mass-related gene expression, and metabolic-pathway readouts.
Receptor-selectivity and safety-pharmacology probes. Ipamorelin is commonly described as a selective ghrelin-receptor agonist, while CJC-1295 is studied as a modified GHRH analogue. Together, the blend provides a research tool for examining complementary endocrine signaling pathways.
Reconstitution Reference
The 10mg combined vial is reconstituted in the laboratory with bacteriostatic water. A common worked example uses 2mL of bacteriostatic water added to the vial, producing a final concentration of 5mg per mL.
The diluent is introduced slowly down the inner wall of the vial while avoiding direct impact on the powder cake. The vial should be gently rolled or swirled until the material is fully dissolved. Vigorous shaking should be avoided.
After reconstitution, the vial is labelled with the reconstitution date, diluent used, concentration, and batch number. This compound is supplied for laboratory research only.
Storage and Handling
Lyophilised vials are stored at -20°C in the original sealed packaging, protected from light and moisture. When the peptide blend has been characterised in stability literature as remaining intact for extended periods, short transit at ambient temperature does not compromise the lyophilised powder.
Once reconstituted with bacteriostatic water, the solution should be stored at 2-8°C in a dedicated laboratory refrigerator and typically used within 14 to 28 days depending on standard peptide-stability references. Repeated freeze-thaw cycles of the reconstituted material should be avoided.
Vials should be labelled with reconstitution date and concentration in accordance with laboratory documentation practice.
References
[2] Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH (1998). Ipamorelin, the first selective growth hormone secretagogue.
[3] Shah DK et al. (2009). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
[4] Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.